Table 1.
Clinicopathological characteristics of 301 patients with PCa from TMA cohort
| Clinicopathological characteristic | Value |
|---|---|
| Age, years | |
| Mean ± SD | 63.54 ± 7.63 |
| Range | 42–85 |
| BMI, kg/m2 | |
| Mean ± SD | 23.21 ± 3.26 |
| Range | 16.23–31.12 |
| T Stage, n (%) | |
| T2 | 140 (46.5) |
| T3 | 128 (42.5) |
| T4 | 33 (11.0) |
| N Stage, n (%) | |
| N0 | 160 (53.2) |
| N1 | 141 (46.8) |
| M Stage, n (%) | |
| M0 | 273 (90.7) |
| M1 | 28 (9.3) |
| Gleason grade group, n (%) | |
| ≤ 6 | 24 (8.0) |
| 3 + 4 | 40 (13.3) |
| 4 + 3 | 82 (27.2) |
| 8 | 83 (27.6) |
| ≥ 9 | 72 (23.9) |
| Diagnostic PSA,ng/ml, n (%) | |
| < 10 | 18 (6.0) |
| 10–20 | 204 (67.8) |
| > 20 | 79 (26.2) |
| Positive surgical margin, n (%) | |
| Yes | 142 (47.2) |
| No | 159 (52.8) |
| Adjuvant therapy, n (%) | |
| Yes | 161 (53.5) |
| No | 140 (46.5) |
| ARPC1A expression, n (%) | |
| (±) | 93 (30.9) |
| ( +) | 114 (37.9) |
| (+ +) | 56 (18.6) |
| (+ + +) | 38 (12.6) |
*P < 0.05